KeyBanc raised the firm’s price target on Bio-Techne (TECH) to $90 from $80 and keeps an Overweight rating on the shares. Overall, fiscal Q2 represented a continuation of last quarter’s strength for Bio-Techne, and the firm believes it is a positive indicator for other life science tools companies.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH: